News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Conference Coverage

3 days ago

elcc

EMPOWER-Lung3 Analysis Reveals Differential Outcomes With Cemiplimab/Chemo in Genomic Subsets of NSCLC

4 days ago

eau

Erda-iDRS Is Safe and Active in FGFR-Altered NMIBC

5 days ago

eau

Novel Enzalutamide Delivery Implant Is Safe and Active in Early-Stage Prostate Cancer

6 days ago

Dr Park on the Role and Benefits of Evaluating MRD in ALL

6 days ago

elcc

Gotistobart Shows Potential as Chemo-Free Option for Treatment-Resistant Squamous NSCLC

6 days ago

elcc

Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC

6 days ago

elcc

Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC

6 days ago

elcc

Dr Hirsch on Validation of an AI-Assisted PD-L1 Scoring Algorithm Against Blueprint Study Data in Lung Cancer

7 days ago

elcc

Frontline Zongertinib Shows Systemic and Intracranial Activity in Advanced HER2-Mutant NSCLC

7 days ago

elcc

Calderasib-Based Therapy Drives High Responses in KRAS G12C–Mutant Metastatic NSCLC

Latest Content

Ovarian Clear Cell Carcinoma | Image Credit: © blueringmedia - stock.adobe.com

Apr 02, 2026 | News

Pembrolizumab Plus Paclitaxel ± Bevacizumab Receives EU Approval for PD-L1+ Platinum-Resistant Ovarian Cancer

STRIDE Plus TACE and Lenvatinib in HCC: ©liver v1: Sebastian Kaulitzki - stock.adobe.com

STRIDE Regimen Shows PFS Benefit Alongside TACE and Lenvatinib in Embolization-Eligible Unresectable HCC

Image Credit: © barinovalena - stock.adobe.com

Dana-Farber Chair of Pathology, Dr. Kathleen Burns, Elected as Fellow of the American Association for the Advancement of Science

US FDA

FDA Approves Brexu-Cel for Relapsed/Refractory MCL

Myelofibrosis | Image Credit: © TheWaterMeloonProjec - stock.adobe.com

Peri-Transplant Ruxolitinib Leads to Low GVHD Incidence in Myelofibrosis

3 experts in this video

Genomic and Longitudinal Risk Assessment in Smoldering Multiple Myeloma

$Amrita Krishnan, MD, shares the significance of the FDA approval of daratumumab plus teclistamab in relapsed/refractory multiple myeloma.$

Dr Krishnan on Implications of the FDA Approval of Daratumumab/Teclistamab in R/R Myeloma

CLL | Image Credit: © Bipul Kumar - stock.adobe.com

Dr Brown on QOL Considerations With Frontline Acalabrutinib/Venetoclax in CLL

Georges Gebrael, MD, University of Utah

Dr Gebrael on Second-Line Therapies After EV-Pembro in Advanced Urothelial Carcinoma

2 experts are featured in this series.

Sequencing Factors in Later-Line Follicular Lymphoma

2 experts are featured in this series.

Navigating Data for Tafasitamab- and Epcoritamab-Based Therapy in R/R Follicular Lymphoma

2 experts are featured in this series.

Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma

5 experts are featured in this series.

Applying Newer Doublets in Practice and Sequencing After Immunotherapy in Advanced RCC

Experts featured in this series.

Assessing Response Beyond Radiographic Tumor Size in Desmoid Tumor

Shorts

Stacy Loeb, MD, NYU Langone

Unpacking the Meaning of Microplastics in Prostate Cancer Samples

2 hours ago

by

Stacy Loeb, MD

Mohammad Arfat Ganiyani, MBBS, Miami Cancer Institute

Examining Real-World Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan

a day ago

by

Mohammad Arfat Ganiyani, MBBS

Marc L Greenwald, MD

Will Neoadjuvant Therapy Reshape the Future of CRC Management?

2 days ago

by

Marc Lehrer Greenwald, MD

Kevin Kalinsky, MD, MS, FASCO

The Potential Role of the SERENA-6 Data in Breast Oncology

3 days ago

by

Kevin Kalinsky, MD, MS

Richard Kim, MD, Moffitt Cancer Center

HPV Prevention and Screening Gaps Continue to Drive Anal Cancer Risk

3 days ago

by

Richard Kim, MD

Luspatercept and Frontline Treatment Decisions in Lower-Risk MDS

Luspatercept and Frontline Treatment Decisions in Lower-Risk MDS

3 days ago

by

Jan Bewersdorf, MD, FACP

OncLive News Roundup for the Week of 3/22

OncLive News Roundup for the Week of 3/22

4 days ago

by

Chris Ryan(+1 more)

Benefits and Limitations of MRI in Soft Tissue Sarcoma Surveillance

BOOM Provides Consensus on Periprosthetic Joint Infection Management in Orthopedic Oncology—but Evidence Gaps Remain

6 days ago

by

R. Lor Randall, MD, FACS

La-Urshalar Brock, FNP, BSN, MSN

The Evolution of Axillary Lymph Node Dissection Practices in Breast Cancer

6 days ago

by

La-Urshalar Brock, FNP, BSN, MSN

What the FDA Approval of Daratumumab Plus Teclistamab Means for R/R Myeloma Care

What the FDA Approval of Daratumumab Plus Teclistamab Means for R/R Myeloma Care

7 days ago

by

Amrita Krishan, MD

Podcasts

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology in Nashville; Neil M. Iyengar, MD, associate professor, co-director, Breast Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, director, Survivorship Services, Winship Cancer Institute of Emory University

Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

D. Ross Camidge, MD, PhD; Alex Alvarez

How a Passion for Justice Leads the Fight in Tobacco Litigation: With D. Ross Camidge, MD, PhD; and Alex Alvarez

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

David Morris, MD, FACS, and Alan H. Bryce, MD

FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD

Oncology Unplugged

HIF-2 Targeting Is Set to Transform Kidney Cancer Management: With Chandler Park, MD; and Katy Beckermann, MD

Continuing Medical Education

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Omid Hamid, MD; Sapna Patel, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Cross-Disease Integration of Immunotherapy Innovations

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Optimizing Treatment for Biliary Tract Cancers

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

11th Annual School of Gastrointestinal Oncology® (SOGO®)

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Addressing Unmet Needs in HER2+ Metastatic BTC

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Proactive Adverse Event Management for HER2+ BTC Treatments

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

All News

HR+, HER2+ Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Palbociclib Plus First-Line Endocrine Maintenance Improves PFS in HR+, HER2+ Advanced Breast Cancer

ByAshling Wahner

April 1st 2026

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Shubham Pant, MD, MBBS

Expanding Therapeutic Options in Pancreatic Cancer and GEP-NETs Highlight the Need for Refined Patient Selection

ByCourtney Flaherty

April 1st 2026

Shubham Pant, MD, MBBS, discusses recent treatment advancements across gastrointestinal malignancies.

Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com

FDA Flashback: Breast Cancer Decisions and News From March 2026

ByAshling Wahner

April 1st 2026

Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.

MDS | Image Credit: © Bipul Kumar - stock.adobe.com

Agent Orange Linked to Aggressive Bone Marrow Cancer in Vietnam Veterans

BySylvester Comprehensive Cancer Center

April 1st 2026

A study identified genetic mutations tied to earlier diagnosis and faster progression of myelodysplastic syndromes.

Bezuclastinib in Patients With imatinib-Treated GIST: © rinrada - stock.adobe.com

FDA Received NDA Submission for Bezuclastinib in Imatinib-Treated GIST

April 1st 2026

Cogent Biosciences has submitted an NDA for bezuclastinib for patients with GIST who received prior imatinib.

FDA

FDA Extends Review of BLA for Orca-T in Hematologic Malignancies

April 1st 2026

The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

March Roundup of FDA Approvals in Oncology: 4 Decisions to Know

March 31st 2026

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

Mazyar Shadman, MD, MPH

Indirect Comparison Associates Zanubrutinib With Improved PFS in Treatment-Naive CLL

March 31st 2026

In a post hoc indirect comparison, data showed zanubrutinib was linked with improved PFS vs acalabrutinib/venetoclax in treatment-naive CLL.

Breast Cancer Data Highlights | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Research Rewind: Phase 3 Breast Cancer Data Highlights From Quarter 1 of 2026

ByAshling Wahner

March 31st 2026

Read our recap of top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

HER2+ Breast Cancer | Image Credit: © peterschreiber.media - stock.adobe.com

Neoadjuvant Anbenitamab Plus Docetaxel Elicits Responses in HER2+ Early Breast Cancer

ByAshling Wahner

March 31st 2026

Neoadjuvant anbenitamab plus albumin-bound docetaxel yielded a significant tpCR benefit vs standard therapy in HER2-positive early breast cancer.

Aggressive Small Cell Lung Cancer | © Image by Ashling Wahner & MJH Life Sciences Using AI

New AI Tool Predicts Whether Aggressive Small Cell Lung Cancer Will Respond to Treatment

ByRoswell Park Comprehensive Cancer Center

March 31st 2026

A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy.

Jeremy Kortmansky, MD, Yale

Rising Rates, Screening Gaps, and Emerging Therapeutic Targets in CRC: Your Key Clinical Questions Answered

ByCourtney Flaherty

March 31st 2026

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.

C. Ola Landgren, MD, PhD, professor, chief, Division of Myeloma, Department of Medicine, director, Sylvester Myeloma Institute, co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, Miller School of Medicine at the University of Miami and the Sylvester Comprehensive Cancer Center

AI Tools Could Drive Improved Risk Stratification, Treatment Decision-Making in Multiple Myeloma

March 31st 2026

C. Ola Landgren, MD, PhD, discusses the development of the AI risk-stratification model CORAL and its potential role in individualizing myeloma care.

Cemiplimab Plus Chemo in Molecularly Defined Subsets of NSCLC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

EMPOWER-Lung3 Analysis Reveals Differential Outcomes With Cemiplimab/Chemo in Genomic Subsets of NSCLC

March 30th 2026

Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

Neil Mendhiratta, MD, MS

Adjuvant Treatment Advances Improve Outcomes in Kidney Cancer but Unmet Needs Persist

March 30th 2026

Neil Mendhiratta, MD, MS, discusses the treatment landscape for patients with kidney cancer during Kidney Cancer Awareness Month.

Trending on OncLive

FDA Approves Brexu-Cel for Relapsed/Refractory MCL

Palbociclib Plus First-Line Endocrine Maintenance Improves PFS in HR+, HER2+ Advanced Breast Cancer

Expanding Therapeutic Options in Pancreatic Cancer and GEP-NETs Highlight the Need for Refined Patient Selection

FDA Flashback: Breast Cancer Decisions and News From March 2026

Dr Krishnan on Implications of the FDA Approval of Daratumumab/Teclistamab in R/R Myeloma